Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bergen Brunswig supply channel cost-control is focus after merger called off.

This article was originally published in The Tan Sheet

Executive Summary

BERGEN SUPPLY EFFICIENCIES WILL REMAIN FOCUS AFTER COLLAPSE OF IVAX MERGER agreement, the wholesaler commented March 20. "One of Bergen Brunswig's central strategies is to pursue opportunities to manage supply channel costs" through in-house programs, alliances or acquisitions, Bergen said. "Notwithstanding the termination of the Ivax agreement, we will continue to pursue our strategy, recognizing the valuable role that generics play."





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts